# GENB (Generate Biomedicines, Inc.) - SEC EDGAR Financial Statements

> Generate Biomedicines, Inc. reported $515.9M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/GENB
- Markdown: https://convexityos.com/fundamentals/GENB.md
- SEC CIK: 0002100782
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:24 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002100782&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $404.2M | Total debt: $75.34M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $4.22M | $6.31M | $7.22M | $9.63M | $10.13M | $8.82M |
| Research & Development | $82.25M | $64.33M | $57.81M | $62.15M | $59.73M | $46.83M |
| Total Operating Expenses | $95.73M | $77.93M | $71.34M | $72.45M | $70.28M | $56.97M |
| **Operating Income** | -$91.51M | -$71.61M | -$64.11M | -$62.81M | -$60.15M | -$48.15M |
| **EBITDA** | -$87.81M | -$68.41M | -$60.84M | -$59.51M | -$56.85M | -$44.74M |
| Interest Income | $4.15M | $4.63M | $2.91M | $3.10M | $3.79M | $4.28M |
| Interest Expense | $192K | $155K | $182K | $253K | $307K | $368K |
| Income Before Tax | -$87.61M | -$67.20M | -$61.69M | -$60.00M | -$56.70M | -$44.26M |
| Income Tax Expense | $49K | $53K | $28K | $34K | $44K | $56K |
| **Net Income** | -$87.66M | -$67.25M | -$61.45M | -$53.62M | -$52.43M | -$41.69M |
| Basic EPS | -$0.68 | -$0.52 | -$1.07 | -$1.97 | -$1.94 | -$1.62 |
| **Diluted EPS** | -$0.68 | -$0.52 | -$1.07 | -$1.97 | -$1.94 | -$1.62 |
| Basic Shares Outstanding | 128.5M | 128.2M | 64.9M | 33.0M | 33.0M | 32.8M |
| Diluted Shares Outstanding | 128.5M | 128.2M | 64.9M | 33.0M | 33.0M | 32.8M |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $140.3M | $135.4M | $160.6M | $121.7M |
| Short-Term Investments | $263.9M | $322.1M | $356.1M | $99.85M |
| **Cash & Short-Term Investments** | $404.2M | $457.4M | $516.6M | $221.5M |
| **Total Current Assets** | $414.6M | $470.3M | $535.4M | $234.4M |
| Property, Plant & Equipment, Net | $38.65M | $27.30M | $27.84M | $29.15M |
| Other Non-Current Assets | $9.34M | $9.06M | $4.75M | $6.81M |
| **Total Non-Current Assets** | $101.2M | $91.44M | $90.35M | $95.82M |
| **Total Assets** | $515.9M | $561.7M | $625.7M | $330.2M |
| Accounts Payable | $7.89M | $5.65M | $7.62M | $3.84M |
| Deferred Revenue (Current) | $7.95M | $12.17M | $17.24M | $21.19M |
| Other Current Liabilities | $3.16M | $2.52M | $2.42M | $2.63M |
| **Total Current Liabilities** | $82.72M | $56.64M | $58.39M | $82.20M |
| Deferred Revenue (Non-Current) | $0 | $0 | $1.24M | $4.51M |
| Other Non-Current Liabilities | $0 | $0 | $0 | $116K |
| **Total Non-Current Liabilities** | $52.01M | $49.01M | $52.55M | $59.35M |
| **Total Liabilities** | $134.7M | $105.6M | $110.9M | $141.6M |
| **Total Debt (incl. Leases)** | $75.34M | $62.63M | $65.57M | $68.53M |
| Common Stock | $129K | $128K | $128K | $33K |
| Retained Earnings | -$892.7M | -$805.0M | -$737.7M | -$676.3M |
| Accumulated Other Comp. Income | -$264K | -$129K | $24K | $106K |
| **Total Stockholders' Equity** | $381.2M | $456.0M | $514.8M | -$616.0M |
| Total Equity | $381.2M | $456.0M | $514.8M | -$616.0M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$87.66M | -$67.25M | -$61.71M | -$60.03M | -$56.74M | -$44.31M |
| Depreciation & Amortization | $3.70M | $3.20M | $3.27M | $3.30M | $3.30M | $3.41M |
| Stock-Based Compensation | $8.06M | $8.24M | $6.39M | $4.82M | $5.49M | $4.74M |
| Change in Receivables | $0 | $0 | $0 | -$105K | $59K | -$91K |
| Change in Payables | $2.24M | -$1.95M | $3.75M | $2.09M | $446K | -$597K |
| **Operating Cash Flow** | -$54.86M | -$57.94M | -$80.39M | -$48.43M | -$48.75M | -$53.18M |
| Capital Expenditure | -$2.15M | -$933K | -$3.78M | -$235K | -$154K | -$751K |
| **Free Cash Flow** | -$57.01M | -$58.88M | -$84.17M | -$48.66M | -$48.91M | -$53.93M |
| Purchases of Investments | -$147.5M | -$606K | -$321.2M | -$22.22M | -$65.16M | -$77.35M |
| **Investing Cash Flow** | $56.36M | $33.31M | -$259.9M | $9.18M | -$17.07M | $75.53M |
| **Financing Cash Flow** | $3.49M | -$579K | $378.9M | $3.79M | -$263K | $20.56M |
| **Net Change in Cash** | $4.99M | -$25.21M | $38.57M | -$35.46M | -$66.08M | $42.92M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 5.01x | 8.30x | 9.17x | -- | -- | -- |
| Quick Ratio | 4.89x | 8.08x | 8.85x | -- | -- | -- |
| Debt to Equity | 0.20x | 0.14x | 0.13x | -- | -- | -- |
| **Revenue Growth (YoY)** | -56.2% | -37.7% | -18.1% | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
